A block-randomized, double-blind, placebo-controlled, single-dose escalating, phase I clinical trial to evaluate the safety, tolerability and pharmacokinetics of YHB1411-2 in healthy male volunteers

Trial Profile

A block-randomized, double-blind, placebo-controlled, single-dose escalating, phase I clinical trial to evaluate the safety, tolerability and pharmacokinetics of YHB1411-2 in healthy male volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Aug 2016

At a glance

  • Drugs YHB 1411-2 (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Yuhan
  • Most Recent Events

    • 14 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Sep 2013 Planned End Date changed from 1 May 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 31 Jul 2013 Planned number of patients changed from 44 to 49 as reported by Clinical Research Information Service (CriS) - Republic of Korea.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top